Market Cap 607.50M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 8.20
Profit Margin -446.89%
Debt to Equity Ratio 1.46
Volume 802,200
Avg Vol 927,072
Day's Range N/A - N/A
Shares Out 54.68M
Stochastic %K 33%
Beta 1.87
Analysts Strong Sell
Price Target $23.86

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
HuntingHighAndLow
HuntingHighAndLow Aug. 3 at 3:52 PM
$ZVRA @KemPharm_rocks 8/2/25 ZVRA “But again, this AI is flawed. IntraBio’s drug is inferior and does not compete with Miplyffa. Ai is still dumb in many respects. How can it compare IntraBio’s product, which treats a few symptoms, to Zevra’s product, which slows or halts the progression of the disease? Zero competition.” Something is indeed flawed, and it’s not the AI. • In the combo therapy, miglustat does most of the heavy lifting; Miplyffa contributes very little for a lot more money • Which is one reason why IntraBio’s drug is increasingly considered the first-line therapy for NPC and why Zevra has a “market access team” to help wangle medical exceptions from payors. • Other reasons include Aqneursa showing superior evidence of improving neurological symptoms and of slowing / halting / reversing disease progression • Worth repeating: reversing disease progression. Too early to make claims about “zero competition” but the evidence points in that direction. https://www.neurology.org/doi/10.1212/WNL.0000000000213589
1 · Reply
intowits
intowits Aug. 3 at 2:22 PM
$ZVRA Apadaz NDA withdrawn: https://www.govinfo.gov/content/pkg/FR-2025-08-04/pdf/2025-14707.pdf
2 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 3 at 1:58 AM
$ZVRA And then there’s this:
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 3 at 12:22 AM
$ZVRA For those of you who keep discounting the importance of value-added-ness of Zevra’s Celiprolol for vEDS to any potential BO suitor:
1 · Reply
Wahoos
Wahoos Aug. 2 at 7:09 PM
$ZVRA If indeed there is an auction bidding process underway, my experience is it is usually completed in a matter of days or maybe 2 weeks at the longest, once the initial bids are received. Now reportedly the initial bids were in the $20+ range. No one in their right mind would surrender this stock at that price. $30 is fair. $25 is a bargain. $35 is abut right to a little rich IMO. In a year, this stock will be at $23-25 or more and buyout bidding starts at $40.
8 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 6:51 PM
$ZVRA So I had been operating under the belief that Zevra would not be able to submit the MMA without a viable European marketing/sales plan (meaning a partnership already in place). This clarified things for me. My assumption was wrong.
0 · Reply
HuntingHighAndLow
HuntingHighAndLow Aug. 2 at 4:31 PM
$ZVRA @EthanStawk 8/1/25 “I find it very unlikely that Corium has a leg to stand on, I figure the lawsuit is specifically to delay a buyout from someone else.” ROFR likely involves Commave in any buyout offer that includes SDX; time added to negotiate is unavoidable. In their opening brief re their motion for partial summary judgment (public version efiled 7/25/25), Zevra advances the stunning idea that Commave’s ROFN and ROFR are disallowed under Delaware’s Uniform Commercial Code: “Commave’s purported rights of first refusal and first negotiation seek to restrict Zevra’s ability to assign, transfer, or create a security interest in royalty payments owed under the License Agreement and are therefore invalid under Delaware law.” Zevra cites no case where such rights have accordingly been ruled invalid, but it is a bold tack that could have enormous implications for contract law…we’ll find out! Until then, looks like Commave is standing on both legs and Zevra is playing on the back foot.
1 · Reply
salems
salems Aug. 2 at 3:36 PM
$ZVRA Next Week should be exciting. If it is fluctuating between 11.50 to 12 and not going below 10.50. That will be great. 3month chart is making cup and handle If it will break 13 resistance then will definitely cross 15 quickly IMO.
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 3:27 PM
$ZVRA The odds of this occurring two straight days in a row 🤔
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 10:26 AM
$ZVRA PR for Q2 EC incoming, next week!
0 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 2 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 4 months ago

Zevra Therapeutics Files Preliminary Proxy


Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:16 PM EDT - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 5 months ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 8 months ago

Zevra Therapeutics Announces Organizational Changes


Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:12 AM EST - 9 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript


US FDA approves Zevra's genetic disorder treatment

Sep 20, 2024, 10:14 AM EDT - 11 months ago

US FDA approves Zevra's genetic disorder treatment


Zevra Therapeutics Expands Executive Leadership Team

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team


Zevra Therapeutics Begins Trading as ZVRA

Wed, 01 Mar 2023 07:43:00 -0500 - 2 years ago

Zevra Therapeutics Begins Trading as ZVRA


HuntingHighAndLow
HuntingHighAndLow Aug. 3 at 3:52 PM
$ZVRA @KemPharm_rocks 8/2/25 ZVRA “But again, this AI is flawed. IntraBio’s drug is inferior and does not compete with Miplyffa. Ai is still dumb in many respects. How can it compare IntraBio’s product, which treats a few symptoms, to Zevra’s product, which slows or halts the progression of the disease? Zero competition.” Something is indeed flawed, and it’s not the AI. • In the combo therapy, miglustat does most of the heavy lifting; Miplyffa contributes very little for a lot more money • Which is one reason why IntraBio’s drug is increasingly considered the first-line therapy for NPC and why Zevra has a “market access team” to help wangle medical exceptions from payors. • Other reasons include Aqneursa showing superior evidence of improving neurological symptoms and of slowing / halting / reversing disease progression • Worth repeating: reversing disease progression. Too early to make claims about “zero competition” but the evidence points in that direction. https://www.neurology.org/doi/10.1212/WNL.0000000000213589
1 · Reply
intowits
intowits Aug. 3 at 2:22 PM
$ZVRA Apadaz NDA withdrawn: https://www.govinfo.gov/content/pkg/FR-2025-08-04/pdf/2025-14707.pdf
2 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 3 at 1:58 AM
$ZVRA And then there’s this:
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 3 at 12:22 AM
$ZVRA For those of you who keep discounting the importance of value-added-ness of Zevra’s Celiprolol for vEDS to any potential BO suitor:
1 · Reply
Wahoos
Wahoos Aug. 2 at 7:09 PM
$ZVRA If indeed there is an auction bidding process underway, my experience is it is usually completed in a matter of days or maybe 2 weeks at the longest, once the initial bids are received. Now reportedly the initial bids were in the $20+ range. No one in their right mind would surrender this stock at that price. $30 is fair. $25 is a bargain. $35 is abut right to a little rich IMO. In a year, this stock will be at $23-25 or more and buyout bidding starts at $40.
8 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 6:51 PM
$ZVRA So I had been operating under the belief that Zevra would not be able to submit the MMA without a viable European marketing/sales plan (meaning a partnership already in place). This clarified things for me. My assumption was wrong.
0 · Reply
HuntingHighAndLow
HuntingHighAndLow Aug. 2 at 4:31 PM
$ZVRA @EthanStawk 8/1/25 “I find it very unlikely that Corium has a leg to stand on, I figure the lawsuit is specifically to delay a buyout from someone else.” ROFR likely involves Commave in any buyout offer that includes SDX; time added to negotiate is unavoidable. In their opening brief re their motion for partial summary judgment (public version efiled 7/25/25), Zevra advances the stunning idea that Commave’s ROFN and ROFR are disallowed under Delaware’s Uniform Commercial Code: “Commave’s purported rights of first refusal and first negotiation seek to restrict Zevra’s ability to assign, transfer, or create a security interest in royalty payments owed under the License Agreement and are therefore invalid under Delaware law.” Zevra cites no case where such rights have accordingly been ruled invalid, but it is a bold tack that could have enormous implications for contract law…we’ll find out! Until then, looks like Commave is standing on both legs and Zevra is playing on the back foot.
1 · Reply
salems
salems Aug. 2 at 3:36 PM
$ZVRA Next Week should be exciting. If it is fluctuating between 11.50 to 12 and not going below 10.50. That will be great. 3month chart is making cup and handle If it will break 13 resistance then will definitely cross 15 quickly IMO.
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 3:27 PM
$ZVRA The odds of this occurring two straight days in a row 🤔
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 2 at 10:26 AM
$ZVRA PR for Q2 EC incoming, next week!
0 · Reply
EthanStawk
EthanStawk Aug. 2 at 7:26 AM
$ZVRA Just a heads up on the broader market after yesterday. Quarter 3 is going to be brutal. We've already seen inflation rising, and that's not including the 10%+ inflationary devaluation of the dollar and the $150 billion in taxes we've paid (or will pay when current inventory that was held before tariffs runs out) from tariffs. The larger issue is what is coming next month, as all of the federal employees that were let go come off the books next month, so if THESE employment numbers looked bad, next quarter is going to be a horror show IMO. That's a whole lot of money that's no longer being used for consumer spending. Just a heads up on what I see coming.
1 · Reply
doctor01
doctor01 Aug. 2 at 3:14 AM
$ZVRA @meadowlarkzac 7:45 PM $ZVRA who is the tape painter? ****************************************** I HEAR THAT HE PAINTS HOUSES TOO.......
2 · Reply
meadowlarkzac
meadowlarkzac Aug. 2 at 12:45 AM
$ZVRA who is the tape painter?
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 1 at 11:22 PM
$ZVRA Always nice to see:
0 · Reply
Cube_CH
Cube_CH Aug. 1 at 9:42 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 1 at 9:30 PM
0 · Reply
YouJackWagon
YouJackWagon Aug. 1 at 9:22 PM
$ZVRA lot of volume to be flat for the day.
0 · Reply
WaynD01
WaynD01 Aug. 1 at 9:18 PM
$ZVRA $NB Today is one of the day that reminds me of the importance of staying invested in ‘certain’ stocks in uncertain times.. ( ignore the last minute rug pull of $ZVRA. ZVRA still fared well in spite of those plays)
0 · Reply
ZVRA100
ZVRA100 Aug. 1 at 9:17 PM
$ZVRA i mean, it’s kinda clean. 11.11
1 · Reply
Smedley1
Smedley1 Aug. 1 at 8:38 PM
$ZVRA another rugpull close
1 · Reply
InvestorRelations_
InvestorRelations_ Aug. 1 at 8:00 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 1 at 7:25 PM
$ZVRA Hang in there my fellow longs, helps a’ comin’ 😉
1 · Reply